OraSure Technologies, Inc. (OSUR)
| Market Cap | 727.19M |
| Revenue (ttm) | 171.72M |
| Net Income (ttm) | -14.92M |
| Shares Out | 67.51M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $10.01 |
| Previous Close | $10.01 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 10.04 |
| Day's Range | 9.70 - 10.10 |
| Day's Volume | 821,293 |
| 52-Week Range | 9.46 - 19.75 |
OraSure Technologies Inc (NASDAQ: OSUR) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for its COVID-19 rapid antigen test for both Prescription Home Use and Professio...
Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow
OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing
BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BETHLEHEM, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 fourth quarter financial results and certain ...
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This is the Eighth EUA to Include a Self-Collection Device from DNA Genotek This is the Eighth EUA to Include a Self-Collection Device from DNA Genotek
OTTAWA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical ser...
BETHLEHEM, Pa., Jan. 26, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...
BETHLEHEM, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...
OraSure: Well Positioned Ex-Covid, Sell Side Missing The Organic Growth Drivers
BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a...
BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...
OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical ser...
BETHLEHEM, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today disclosed that the U.S. Foo...
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen ...
BETHLEHEM, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in the fight against HIV, today announced its plans to commemorate World AIDS Day. On Tuesday, Dec. ...
BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...
A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stock Upgrades: Orasure Technologies Shows Rising Relative Strength appeared first on Investor...
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript
OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Net T hird Q uarter R evenues of $ 48.0 M illion Increased 33 % Year-Over-Year, D riven by $ 18 . 4 M illion in S ales of O ral F luid C ollection D evices for COVID-19 M olecular T esting
Second FDA EUA for the Subsidiary's Saliva Collection Devices Second FDA EUA for the Subsidiary's Saliva Collection Devices
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.
BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and certain b...
The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.
OraSure Technologies (OSUR) is in the news Monday after announcing approval from the FDA for one of its devices sent OSUR stock soaring. The post OraSure Technologies News: Why OSUR Stock Is Surging 13%...
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) were advancing strongly Monday after the diagnostic company said its DNA Genotek subsidiary's saliva collection device used in COVID-19 testing has be...
OraSure Technologies Inc. (NASDAQ: OSUR) shares jumped to start off the week after the company announced an update from the U.S.
BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...
Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.
BETHLEHEM, Pa., Sept. 24, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...
A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to an article ...
BETHLEHEM, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and ana...
BETHLEHEM, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and a...
A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stocks With Rising Relative Price Strength: Orasure Technologies appeared first on Investor's...
OraSure Technologies, Inc. (OSUR) CEO Steve Tang on Q2 2020 Results - Earnings Call Transcript
OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BETHLEHEM, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...
BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and anal...
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET
MORRISVILLE, N.C., June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to brin...
OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical s...
BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analy...
The number of EUAs utilizing OraSure’s saliva collection products continues to grow The number of EUAs utilizing OraSure’s saliva collection products continues to grow
BETHLEHEM, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR) (“OraSure” or the “Company”) today announced the full exercise by the underwriters of their option to purcha...
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Nov 12, 1986 |
| CEO Stephen Tang | Employees 570 |
| Stock Exchange NASDAQ | Ticker Symbol OSUR |
Analyst Forecasts
According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 69.83% from the latest price.